These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 17726225)
1. Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. Hill JM; Hauser JM; Sheppard LM; Abebe D; Spivak-Pohis I; Kushnir M; Deitch I; Gozes I J Mol Neurosci; 2007; 31(3):183-200. PubMed ID: 17726225 [TBL] [Abstract][Full Text] [Related]
2. Vasoactive intestinal peptide antagonist treatment during mouse embryogenesis impairs social behavior and cognitive function of adult male offspring. Hill JM; Cuasay K; Abebe DT Exp Neurol; 2007 Jul; 206(1):101-13. PubMed ID: 17521630 [TBL] [Abstract][Full Text] [Related]
3. Neonatal mice of the Down syndrome model, Ts65Dn, exhibit upregulated VIP measures and reduced responsiveness of cortical astrocytes to VIP stimulation. Sahir N; Brenneman DE; Hill JM J Mol Neurosci; 2006; 30(3):329-40. PubMed ID: 17401158 [TBL] [Abstract][Full Text] [Related]
4. Vasoactive intestinal peptide (VIP) regulates activity-dependent neuroprotective protein (ADNP) expression in vivo. Giladi E; Hill JM; Dresner E; Stack CM; Gozes I J Mol Neurosci; 2007; 33(3):278-83. PubMed ID: 17952637 [TBL] [Abstract][Full Text] [Related]
5. Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior. Lim MA; Stack CM; Cuasay K; Stone MM; McFarlane HG; Waschek JA; Hill JM Int J Dev Neurosci; 2008 Aug; 26(5):423-34. PubMed ID: 18423945 [TBL] [Abstract][Full Text] [Related]
6. Neurobehavioral development of neonatal mice following blockade of VIP during the early embryonic period. Wu JY; Henins KA; Gressens P; Gozes I; Fridkin M; Brenneman DE; Hill JM Peptides; 1997; 18(8):1131-7. PubMed ID: 9396053 [TBL] [Abstract][Full Text] [Related]
7. VPAC receptor signaling modulates grouping behavior and social responses to contextual novelty in a gregarious finch: a role for a putative prefrontal cortex homologue. Kingsbury MA; Miller KM; Goodson JL Horm Behav; 2013 Aug; 64(3):511-8. PubMed ID: 23899763 [TBL] [Abstract][Full Text] [Related]
8. Severe microcephaly induced by blockade of vasoactive intestinal peptide function in the primitive neuroepithelium of the mouse. Gressens P; Hill JM; Paindaveine B; Gozes I; Fridkin M; Brenneman DE J Clin Invest; 1994 Nov; 94(5):2020-7. PubMed ID: 7962548 [TBL] [Abstract][Full Text] [Related]
9. Deficits in social behavior and reversal learning are more prevalent in male offspring of VIP deficient female mice. Stack CM; Lim MA; Cuasay K; Stone MM; Seibert KM; Spivak-Pohis I; Crawley JN; Waschek JA; Hill JM Exp Neurol; 2008 May; 211(1):67-84. PubMed ID: 18316078 [TBL] [Abstract][Full Text] [Related]
11. VIP receptor subtypes in mouse cerebral cortex: evidence for a differential localization in astrocytes, microvessels and synaptosomal membranes. Martin JL; Feinstein DL; Yu N; Sorg O; Rossier C; Magistretti PJ Brain Res; 1992 Jul; 587(1):1-12. PubMed ID: 1326373 [TBL] [Abstract][Full Text] [Related]
12. Differential regulation of activity-dependent neuroprotective protein in rat astrocytes by VIP and PACAP. Zusev M; Gozes I Regul Pept; 2004 Dec; 123(1-3):33-41. PubMed ID: 15518891 [TBL] [Abstract][Full Text] [Related]
13. Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design. Gozes I; Perl O; Giladi E; Davidson A; Ashur-Fabian O; Rubinraut S; Fridkin M Proc Natl Acad Sci U S A; 1999 Mar; 96(7):4143-8. PubMed ID: 10097177 [TBL] [Abstract][Full Text] [Related]
14. Involvement of pituitary adenylate cyclase-activating polypeptide II vasoactive intestinal peptide 2 receptor in mouse neocortical astrocytogenesis. Zupan V; Hill JM; Brenneman DE; Gozes I; Fridkin M; Robberecht P; Evrard P; Gressens P J Neurochem; 1998 May; 70(5):2165-73. PubMed ID: 9572304 [TBL] [Abstract][Full Text] [Related]
15. Vasoactive intestinal peptide in the brain of a mouse model for Down syndrome. Hill JM; Ades AM; McCune SK; Sahir N; Moody EM; Abebe DT; Crnic LS; Brenneman DE Exp Neurol; 2003 Sep; 183(1):56-65. PubMed ID: 12957488 [TBL] [Abstract][Full Text] [Related]